<DOC>
	<DOCNO>NCT00984438</DOCNO>
	<brief_summary>The purpose research study try identify effective treatment plan improve survival rate patient recurrent Glioblastoma Multiforme ( GBM ) brain tumor remove brain surgery . The study record effect ( good bad ) combination surgery chemotherapy wafer insert spot patient 's tumor surgery post-operative chemotherapy patient survival rate next 12 month .</brief_summary>
	<brief_title>Surgery With Implantable Biodegradable Carmustine ( BCNU ) Wafer Followed Chemo Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Histopathologically proven diagnosis GBM past MRI finding compatible disease recurrence . Multifocal disease permit . Must prior treatment standard dose Temodar KPS &gt; 50 ; ECOG &lt; 3 Predicted life expectancy &gt; 3 month Study entry must within 5 week surgical resection Prior exposure VEGF inhibitor Irinotecan Intracranial bleed define CT MRI le 6 month prior entry GI bleed less 6 month prior entry Uncontrolled concurrent illness would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>